glp 1 agonists vs sglt2 inhibitors SGLT-2 and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease Cardiorenal Protection: Potential of SGLT2

Start with our quiz to find the right Nutrisense program to help you take control

Biochem Biophys Res Commun 2018;505:523-9.ArticlePubMed 63

Greenway, F.L

Indeed, obesity, often present in people with T2D, is also a major risk factor for CKD development (4), as are associated conditions such as elevated blood pressure and dyslipidemia

Instead, they require patience and a long-term approach to achieve meaningful results

Biological effects of GIP The Gastric Inhibitory Polypeptide (GIP), isolated for the first time from porcine small intestine in 1971 [27], was named as GIP on the basis of its ability to inhibit gastric hydrochloric acid secretion [28]